AKT1 and neoplasm: Consistently, a study reported that specifically targeting PD-L1 with monoclonal antibodies resulted in decreased glycolysis in tumor cells via an obstruction of the PI3K/Akt/mTOR pathway and the translation of glycolytic enzymes, thereby improving the anti-tumor function of T cells [55].